Introduction
Vascular endothelial growth factor (VEGF or VEGF-A) is an essential angiogenic factor during development, in physiological blood vessel formation in the adult and in the pathogenesis of cancer and eye disease (Carmeliet and Jain, 2003; Ferrara et al., 2003) . VEGF exerts its diverse biological effects in endothelial cells through high-affinity binding with two tyrosine-kinase receptors, Flt-1 (VEGFR1) and KDR (VEGFR2) (Neufeld et al., 1999; Zachary, 2003) . KDR is activated through ligandstimulated receptor dimerization and trans(auto)phosphorylation of multiple tyrosine residues in the cytoplasmic domain (Dougher and Terman, 1999; Takahashi et al., 2001) , triggering an array of early signalling events mediating cellular biological responses, including production of prostacyclin and nitric oxide, increased cell survival, migration, proliferation and angiogenesis (Waltenberger et al., 1994; Xia et al., 1996; Abedi and Zachary, 1997; Laitinen et al., 1997; Wheeler-Jones et al., 1997; Gerber et al., 1998; AbuGhazaleh et al., 2001; Gliki et al., 2001; Takahashi et al., 2001; Zachary, 2003) . The role of gene expression in endothelial functions regulated by VEGF-A 165 is still poorly understood, but recent findings from cDNA and oligonucleotide array screening have identified the endothelial gene expression profile induced by VEGF-A 165 (Abe and Sato, 2001; Liu et al., 2003) . We identified four immediate-early genes that were most strongly upregulated by VEGF, early growth response 3 (Egr3), and the NR4A1 family of nuclear receptors (Nur77), NR4A2 (Nurr1) and NR4A3 (Nor1). These immediate-early genes may play key roles in the orchestration of long-term biological functions essential for the angiogenic response to VEGF. In the present study, this possibility was investigated by analysing the functional relevance of Egr3 and Nur77 in human endothelial cells.
The Egr family comprises four members, Egr1, Egr2, Egr3 and Egr4, all characterized by a highly conserved DNA-binding domain composed of three Cys2-His2 zinc-finger motifs recognizing a nine-base-pair segment of DNA (GCGGGGGCG), with each finger spanning three nucleotides (O'Donovan et al., 1999) . Egr1, -2 and -3 are transcriptional activators, whereas Egr4 is a transcriptional repressor. Egr1 is induced by diverse stimuli, including growth factors and cytokines, and is involved in cell proliferation and differentiation in a variety of tissues and cells, including endothelial cells (Fahmy et al., 2003) . Egr3, like Egr1, is also upregulated by various stimuli, including serum, growth factors and hormones (Levkovitz et al., 2001; Mercier et al., 2001; Inoue et al., 2004) . Studies in mice either deficient in Egr3 or over-expressing Egr3 indicate that this transcription factor is involved in the regulation of T-cell activation, survival and proliferation. (Xi and Kersh, 2004a,b; Safford et al., 2005) . Egr3 is regulated by nerve cell growth factor and is also implicated in neuronal axon outgrowth (Levkovitz et al., 2001) . Egr3-deficient mice lacked muscle spindles and displayed severe abnormalities in motor functions (Tourtellotte and Milbrandt, 1998) , consistent with a requirement of Egr3 in muscle-spindle development (Tourtellotte et al., 2001) . The NR4A nuclear receptor subfamily comprises Nur77 (NR4A1), Nurr1 (NR4A2) and Nor1 (NR4A3), which are transcription factors with roles in differentiation, proliferation and apoptosis in various cell types. However, studies of Nur77 in endothelial cells have yielded differing results. Adenoviral overexpresion of Nur77 in human umbilical vein endothelial cells (HUVECs) caused cell cycle arrest (Arkenbout et al., 2003) , whereas inhibition of Nur77 protein expression suppressed VEGF-induced angiogenesis .
In the present study, we show that VEGF preferentially upregulates Egr3 in endothelial cells and causes Egr-dependent transcriptional activation. Suppression of Egr3 expression using small interfering (si) RNAmediated gene silencing reduced VEGF stimulation of endothelial cell proliferation, migration and tubulogenesis, and also increased basal levels of apoptosis, indicating a novel role for this transcription factor in the angiogenic response to VEGF.
Results

VEGF regulation of Egr transcription factors and Egr transcriptional activation
Examination of Egr family expression using both nonquantitative and quantitative real-time RT (reverse transcriptase)-PCR showed that VEGF induced predominantly Egr3 gene expression and modestly enhanced Egr2 gene expression, but caused little change in Egr1 gene expression (Figures 1a and b) . VEGF-induced Egr3 gene expression was 60-fold above the basal expression, 5-fold higher than VEGF-mediated Egr2 gene expression and 12-fold greater than Egr1 expression.
The effect of VEGF on Egr-dependent transcriptional activation was determined in nuclear extracts using a nonradioactive binding assay (NoShift II transcription factor assay), which measures nuclease protection of Egr response elements by binding with nuclear factors. There was a 2.5-fold increase in Egr transcription activation in VEGF-treated cells in comparison with untreated cells. Time-course experiments revealed that VEGF-mediated Egr activation reached a peak at 45 min, which was maintained for 90 min and gradually diminished after 3 h, returning to the basal level after 5 h ( Figure 1c ). We previously reported that VEGF-induced Egr3 mRNA expression was mediated via KDR, PKC and extracellular signal-regulated kinase (ERK) signalling pathways (Liu et al., 2003) . In order to examine whether Egr transcriptional activation was mediated through the same signalling pathways, HUVECs were preincubated with SU5614, GF109203X and U0126, Figure 1 Vascular endothelial growth factor (VEGF) regulation of Early growth response (Egr) gene expression and transcriptional activation. (a, b) Cells were incubated in 0.3% FCS/EBM overnight and then were incubated with serum-free basal medium and no addition (C) or 25 ng ml -1 VEGF (V) for 45 min. RNA was extracted and gene expression was examined by conventional PCR (a) and quantitative real-time RT-PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a reference gene (b) . The values in panel b represent mean fold increases±s.e.m. in mRNA expression above the control level (basal EBM) normalized to GAPDH. (c) Cells were incubated with 25 ng ml -1 VEGF for the times indicated, nuclear extracts were prepared and Egr transcriptional activation was measured by the NoShift assay. Data are expressed as mean fold increases±SEM above the level in unstimulated cells obtained from three independent experiments. (d) Cells were preincubated as indicated with 5 mM SU5614, 10 mM U0126 or 3 mM GF109203X (GFX) for 30 min prior to treatment with 25 ng ml -1 VEGF in basal EBM for a further 45 min. All samples were incubated with an equivalent volume of solvent dimethylsulphoxide. Nuclear extracts were prepared and Egr transcription activation was examined by the NoShift assay. Data are expressed as mean fold increases±s.e.m. above the level in unstimulated cells obtained from three independent experiments. *Po0.05, **Po0.01 for inhibitor vs VEGF alone. (Zugaza et al., 1996) . VEGF induced a striking increase in PKD phosphorylation at serines 744 and 748, essential for PKC-mediated activation of PKD. PKD activation was inhibited by the KDR inhibitor SU5614 and the PKC inhibitor GF109203X, but was unaffected by inhibitors of classical PKC isoforms (Go¨6976), p38 MAPK (SB203580) and the extracellular signalregulated kinase cascade (U0126), indicating that VEGF-induced PKD phosphorylation in HUVECs was mediated through a nonclassical PKC pathway (Figure 2a ). The role of PKD in VEGF-induced Egr3 expression was examined by knockdown of PKD1 and PKD2 protein expression using specific siRNA (Figure 2b ). An antibody that recognizes total PKD detected two bands as a doublet. Cells transfected with 
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PKD1-specific siRNA markedly reduced expression of the higher molecular weight band recognized by total PKD antibody in comparison with negative control siRNA-treated cells (Figure 2b ), whereas PKD2-specific siRNA inhibited expression of the lower molecular weight band and strongly inhibited expression of a single major band recognized by a PKD2-specific antibody ( Figure 2b ). PKD1 knockdown caused a 60% reduction in VEGF-induced Egr3 gene expression compared with negative control siRNA, while PKD2 siRNA reduced Egr3 expression by 40% (Figure 2c ). Interestingly, comparison with the effects of PKD knockdowns on VEGF-induced expression of the NR4A family member, Nur77, showed no effect of PKD1 siRNA but a 45% reduction in Nur77 expression in cells transfected with PKD2 siRNA (Figure 2d ). Our results indicated that VEGF-induced Egr3 gene expression was mediated via PKC-dependent activation of PKD1 and PKD2, whereas VEGF-induced Nur77 gene expression was partially dependent on PKD2 only.
Egr3 siRNA inhibited endothelial cell growth Since Egr3 is the major form of Egr transcription factor induced by VEGF, we examined the functional role of this transcription factor by targeted knockdown using RNA interference. Our previous findings demonstrated that FGF-2 also significantly upregulated Egr3 expression, but caused a much smaller increase in expression of the NR4A gene family (Liu et al., 2003) . The induction of Egr3 by FGF-2, although weaker than that of VEGF (Figure 3a ), prompted us to also examine the effects of Egr3 siRNA on the biological response to FGF-2. In addition, we investigated the effects of siRNA-mediated knockdown of Nur77, the member of the NR4A nuclear receptor subfamily, most strongly induced by VEGF (Liu et al., 2003) .
Egr3 and Nur77 siRNAs markedly reduced both basal mRNA expression and mRNA expression induced by VEGF or FGF-2 (Figures 3a and b) . Next, we evaluated the functional effects of Egr3 and Nur77 siRNAs on cell proliferation stimulated by VEGF and FGF-2. Transfection of siRNA against Egr3 significantly reduced the increase in cell number induced by VEGF and FGF-2 by 22 and 40%, respectively (Figure 4a ), while knockdown of Nur77 mRNA reduced the increase in cell number by 40 and 45%, respectively (Figure 4b ). Egr3 and Nur77 knockdown also markedly reduced the increase in viable cells caused by VEGF or FGF-2 treatment determined by XTT (sodium 3 0 [1-(phenlaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate assay (Figure 4c ). In comparison with negative control siRNA, Egr3 knockdown inhibited the increase in cell viability in VEGF-treated cells and FGF-2-treated cells by 40 and 37%, respectively. Corresponding inhibitory effects of Nur77 knockdown on cell viability were 32 and 35%, respectively.
To examine whether Egr3 knockdown affected endothelial cell survival, annexin-V binding to intact cells was determined using FACS analysis. Egr3 siRNA transfection caused a marked inhibition of cell survival under basal conditions (no growth factor treatment) as indicated by an increase in annexin V þ cells and decrease in the number of nonapoptotic cells compared with negative control siRNA, but had no significant effect on the antiapoptotic responses to VEGF and FGF-2 (results not shown). Nur77 siRNA had no significant effect on either the basal level of apoptosis in HUVECs or the prosurvival effects of VEGF or FGF-2. These findings indicate that while Egr3 contributes to endothelial cell survival under basal conditions, it is not important for survival pathways induced by VEGF or FGF-2.
Inhibition of Egr3 gene expression suppressed endothelial cell migration Vascular endothelial growth factor is a potent chemoattractant for endothelial cells, and the migratory response to VEGF plays a key role in VEGF-driven angiogenesis. Therefore, we also examined whether Egr3 or Nur77 knockdown had any effect on VEGF-induced chemotaxis. As shown in Figure 5 , transfection of HUVECs with Egr3 or Nur77 siRNAs reduced the number of cells migrating in response to VEGF by 55 and 60%, respectively, compared with a negative control siRNA. 
Egr3 siRNA inhibited in vitro angiogenesis Next, we tested the role of Egr3 and Nur77 in the angiogenic response to VEGF by determining the effects of siRNAs on the ability of endothelial cells to form tubule-like structures in a collagen gel. Untransfected HUVECs became organized into capillary-like networks with highly organized three-dimensional structures when incubated in collagen gels for 24 h (Figure 6a ). Both VEGF (25 ng ml 
Discussion
Angiogenesis is a complex multistep process involving endothelial basement membrane degradation, cell migration, proliferation, canalization, branching and maturation of neovessels. VEGF is a pivotal mediator of this process, but while the array of endothelial genes upregulated by VEGF has been described (Abe and Sato, 2001; Liu et al., 2003) , the role of individual gene functions regulated by VEGF is poorly understood. A previous study reported that inhibition of Egr1 protein expression by DNAzymes blocked serum-induced proliferation and migration and perturbed pre-existing tubular structures in Matrigel (Fahmy et al., 2003) . Upregulation of Egr1 by FGF-2 in endothelial cells is also thought to play a pivotal role in inducing proangiogenic factors (Silverman and Collins, 1999) . Furthermore, Nur77, which is strongly upregulated by VEGF, is implicated in mediating endothelial cell proliferation stimulated by VEGF .
Our previous work reported that Egr3 was one of the genes most strongly upregulated by VEGF in a screen of oligonucleotide arrays (Liu et al., 2003) . At the 45 min time point, Egr3 is the most strongly upregulated form of the Egr family in response to VEGF as compared to other Egr family members. Although the total amount of Egr1 and Egr2 mRNA was not quantified at different time points, we assumed that Egr3 could be the predominant form induced by VEGF. To date, however, the role of Egr3 in endothelial cell functions has not Figure 4 Egr3 and Nur77 knockdown suppresses endothelial cell proliferation. (a, b) Cells were transfected with control (C), Egr3 (a) or Nur77 (b) siRNAs. Cells were seeded in 24-well plates 24 h after siRNA transfection with complete medium for 4 h, and medium was then replaced by 0.5% FCS/EBM containing no addition (À), 25 ng ml -1 VEGF or 25 ng ml -1 FGF-2 for a further 72 h. Cells in each well were then detached and counted using a Sysmex CDA-500 cell counter. Experiments were performed 4-7 times and each treatment was performed in triplicate. Data represent mean ± s.e.m. fold increases in cell number above the value in cells transfected with control siRNA. (c) Cells were seeded in 96-well plates 24 h after siRNA transfection and then treated for 72 h with growth factors as described for panels a and b. Viable cells were then measured by XTT assay. The data shown represent results from four independent experiments and are expressed as mean ± s.e.m. fold increases in viable cells above the control. For (a-c), *Po0.05, **Po0.01 for Egr3 or Nur77 siRNA vs control siRNA obtained using two-way ANOVA analysis. Figure 5 Egr3 and Nur77 siRNA knockdown inhibits endothelial cell migration. Cells were transfected with siRNAs or mock transfected (no siRNA) as indicated, and 48 h later a single cell suspension was seeded on top of the PET membrane of transwells, with serum-free basal EBM containing either no addition (À) or 25 ng ml -1 VEGF in the bottom of the well. Cells were allowed to migrate for 4 h. Migrated cells were stained with Diff Quick. Four fields of cells from each membrane were counted using a graticule. Results represent mean ± s.e.m. numbers of migrated cells per field obtained from four independent experiments with each treatment performed in duplicate wells. *Po0.05 for Egr3 or Nur77 vs control siRNA.
VEGF Regulation of Egr3 D Liu et al been investigated. Egr3 expression is mitogenically induced in fibroblasts (Patwardhan et al., 1991) and is upregulated by electroconvulsive stimulation in hippocampal granule cells and other neuronal activity (O'Donovan et al., 1998), but the role of regulation by growth factors in cell types other than neurons or T cells has not previously been widely investigated. The discovery that transcriptional regulators, such as the NGFI-A-binding proteins called NABs, can suppress Egr-mediated mRNA expression suggests that changes in Egr3 mRNA levels are not the only determinant of transcriptional activation dependent on this factor (O'Donovan et al., 1999) . However, VEGF-induced Egr transcriptional activation and both Egr3 mRNA upregulation and transcriptional activation were blocked by specific inhibitors of KDR, PKC and ERK pathway, indicating that the same signalling pathway mediated these responses. Furthermore, VEGF induction of Egr3 mRNA expression (Liu et al., 2003) and Egr transcriptional activation initially increased with similar kinetics, both reaching a peak after 45 min, although transcriptional activation persisted for 90 min and slowly returned to the basal level after 5 h, whereas increased gene expression returned to near basal level after 90 min. This is consistent with a more sustained effect of the protein product following the initial burst of de novo gene expression. Taken together, these findings are consistent with the conclusion that Egr transcriptional activation is primarily mediated through Egr3, although we do not preclude the possibility that other Egr family members are also involved. 
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Currently, there is surprisingly little knowledge of the key transcription factors that mediate long-range angiogenic effects of VEGF either during development or in adult physiology or disease. The major finding of this paper is that Egr3 gene silencing in HUVECs inhibited VEGF-induced Egr3 upregulation, cell proliferation, cell migration and tubulogenesis, thus identifying Egr3 as one of the few transcription factors known to regulate VEGF-dependent angiogenic responses. Egr3 knockdown also strongly increased the basal level of apoptosis in HUVECs, but interestingly had no effect on the antiapoptotic response to VEGF. Presumably, Egr3 is required to maintain constitutive survival mechanisms, but is dispensable for VEGF-induced survival pathways. Egr3 is important for proliferative and survival signals in thymocytes (Xi and Kersh, 2004a,b; Xi et al., 2006; Carter and Tourtellotte, 2007) , but has not previously been implicated in endothelial cell responses. Furthermore, Egr3 knockdown also strongly inhibited tubulogenesis and proliferation induced by the angiogenic factor FGF-2. FGF-2 induced a significant increase in Egr3 mRNA expression (Liu et al., 2003) , although its effect was considerably less than that of VEGF. The findings that Egr3 gene silencing inhibited survival in unstimulated cells and suppressed FGF-2 tubulogenesis in vitro suggests that basal levels of this transcription factor may be important for endothelial functions. However, FGF-2 strongly upregulates VEGF expression in models of tubulogenesis , and its biological effects in endothelial cells are at least partly mediated through VEGF, suggesting that inhibition of FGF-2 responses may be secondary to suppression of VEGF responsiveness.
We also examined the effects on endothelial functions of knockdown of Nur77, a transcriptional regulator belonging to the NR4A family of nuclear receptors, also strongly upregulated by VEGF (Liu et al., 2003) . Previous studies reported differing effects of manipulation of Nur77 levels in endothelial cells: Arkenbout et al. (2003) found that overexpression of Nur77 decreased mitogenic responsiveness, whereas Zeng et al. (2006) showed that Nur77 overexpression induced angiogenesis and Nur77 antisense inhibited VEGF-driven angiogenesis. Our results demonstrated that Nur77 siRNA was effective in suppressing VEGF-induced Nur77 mRNA expression and also markedly decreased VEGF-dependent cell proliferation, migration and tubulogenesis, although in contrast to Egr3 knockdown, Nur77 siRNA had little effect on basal or VEGF-dependent cell survival. These findings are broadly consonant with the conclusions of Zeng et al. and support a role for Nur77 in VEGF-induced angiogenesis.
Protein kinase C is a key mediator of VEGF/ VEGFR2 signalling, and recent findings indicate that PKD is a major downstream effector of PKC-dependent pathways in response to VEGF (Wong and Jin, 2005; Qin et al., 2006) . The finding that inhibition of PKD1 and PKD2 protein expression significantly decreased Egr3 gene expression indicates a role for PKC-dependent activation of PKD1 and PKD2 in VEGF-induced Egr3 gene expression. In addition, knockdown of PKD2, but not PKD1, also significantly attenuated Nur77 expression. PKD1 has previously been reported to undergo translocation to the nucleus in fibroblastic cells (Rey et al., 2001) , suggesting that PKD1 may be a proximate mediator of transcriptional upregulation, a possibility that warrants further study.
Our findings indicate that Egr3, probably together with other Egr isoforms, plays an important role in angiogenesis. Egr3
À/À and Nur77 À/À mice have no overt vascular phenotype, indicating that neither of these transcriptional regulators plays essential roles in angiogenesis or vascular maturation during development. However, adult Nur77-deficient mice show reduced tumour growth associated with decreased tumour vascularization . While further work is required to investigate the role of Egr3 in angiogenesis in vivo, the findings that VEGF strongly upregulates Egr3 and that suppression of Egr3 mRNA expression markedly inhibits angiogenic responses to VEGF suggest that ectopic Egr3 upregulation in endothelial cells may be important for adult angiogenesis possibly related to diseases such as cancer. Further studies will be essential to understand the importance of VEGFinduced Egr3 expression for angiogenesis in health and disease, and to identify the downstream targets of Egr3 transcriptional activation important for endothelial functions of this factor.
Materials and methods
Materials
Recombinant human VEGF-A 165 and basic FGF (FGF-2) were purchased from R&D Systems (Abingdon, Oxon, UK). SU5614, GF109203X, Go6976, U0126, SB203580 were purchased from Calbiochem Inc. (Nottingham, UK). Antibodies to total PKD, phospho-PKD and total MAPK were from Cell Signaling Technology (Beverley, MA, USA). PKD2 antibody was from Bethyl Laboratories Inc. (Montgomery, TX, USA).
Cell culture and treatments
Human umbilical vein endothelial cells were purchased from TCS CellWorks (Buckinghamshire, UK). The cells were cultured in endothelial basal medium (EBM) supplemented with 10% fetal bovine serum (FBS), 10 ng ml -1 human epidermal growth factor (hEGF), 12 mg ml -1 bovine brain extract, 50 mg ml -1 gentamicin sulphate and 50 ng ml -1 amphotericin-B (Cambrex, Wokingham, Berks, UK). For experimental purposes, fully confluent HUVECs at passages 2-3 were preincubated in EBM with 0.3% FBS in the absence of other supplements overnight. The cells were subsequently washed to remove residual serum and preincubated with SU5614 (SU) (5 mM), U0126 (U0) (10 mM), bisindolylmaleimide I (GFX) (3 mM), Go6976 (Go) (1 mM) and SB203580 (SB) (5 mM) at the indicated concentrations for 30 min before treatment with VEGF in basal EBM for 45 min. The cells were washed twice with PBS prior to RNA extraction and other procedures.
siRNA transfection
The cells were cultured in six-well plates until confluent. For transfections, chemically synthesized duplex siRNAs directed VEGF Regulation of Egr3 D Liu et al against human Egr3, Nur77, PKD1 and PKD2 and a nontargeted control siRNA were used. ON-TARGETplus Egr3 siRNA (J-006528-07) was purchased from Dharmacon (Lafayette, CO, USA) and PKD1 (siRNA ID 317), PKD2 (siRNA ID 1013) and control siRNAs were purchased from Ambion (Warrington, UK). Nur77 siRNA was purchased from Qiagen (West Sussex, UK). A concentration of 200 nM siRNA was diluted with OptiMEM (Invitrogen Ltd, Paisley, UK) in the final volume of 180 ml. A 10 ml volume of oligofectamine (Invitrogen) and 10 ml volume of OptiMEM I (Invitrogen) were premixed in a separate tube. Both mixtures were allowed to incubate at room temperature for 10 min, and were then combined and incubated for 25 min at room temperature. The cells were washed with OptiMEM once and transferred to 0.8 ml of fresh OptiMEM. The siRNAoligofectamine mixture was then overlaid dropwise on to cells and incubated for 4 h, before the addition of 500 ml of 30% FCS/OptiMEM. The medium was replaced by complete EBM after 24 h.
Cell proliferation
Cell proliferation was assessed by direct cell counting. At 24 h after siRNA transfection, cells were detached by trypsin and EDTA and seeded at 10 000 per well in a 24-well plate with complete EBM. After 4 h, cells adhered in the 24-well plate. The complete medium was then replaced by fresh 0.5% FCS/ EBM with or without growth factors as indicated. Cell numbers were determined by a Sysmex CDA-500 cell counter after 72 h.
Cell proliferation was also assessed by an assay of viable cells, based on the ability of metabolic cells to convert XTT (Roche Diagnostics, East Sussex, UK) to formazan dye. 5 Â 10 3 Cells were seeded into each well of 96-well plates in complete medium. After 4 h, cells were washed once in serumfree EBM and transferred to 0.5% FCS/EBM in the presence or absence of growth factors and incubated for up to 72 h. For the last 16 h, in each well of 96-well plates, a 50 ml mixture of 5 ml of XTT labelling reagent and 100 ml of electron-coupling reagent was added to cells. Absorbance was measured 16 h later using a Tecan plate reader at 492 nm with reference wavelength 595 nm.
Collagen gel tubulogenesis assay Collagen gels were prepared by mixing 8 volumes of PuroCol (Nutacon BV, Leimuiden, The Netherlands) containing 99.9% type I bovine collagen with 1 volume of 10 Â medium 199 (Invitrogen) and 1 volume of 0.1 N NaOH; the mixture was then kept on ice. The mixed solution was neutralized by addition of 0.5 N NaOH. A 750 ml volume of this reconstituted collagen solution were placed in each well of 12-well tissue culture plates and immediately incubated at 37 1C for 1 h to allow gelation. After the gel had solidified, cells were detached by trypsin and EDTA, and trypsin was inhibited by trypsin neutralizing solution (TNS; Cambrex). 2.5 Â 10 5 cells were mixed with 0.5% FCS/EBM in the presence or absence of growth factors as indicated and then incubated at 37 1C for 24 h. Photographs were taken using a phase-contrast microscope, and tubular structures were quantified using NIH Image 1.63 software.
Apoptosis assay
Confluent HUVECs were transfected with siRNA as indicated and 24 h posttransfection, the cells were switched to complete EBM for 4 h before incubation in serum-free medium 199 with or without growth factors for another 24 h. The cells were then detached, collected by centrifugation and stained with fluorescein-conjugated annexin V and propidium iodide (Roche Dignostics, San Jose, CA, USA). The stained cells were analysed by flow cytometry using a FACSCalibur (Becton Dickinson). Annexin V þ cells are apoptotic cells; cells that were propidium iodide-positive and annexin V negative were not counted as apoptotic cells.
Migration assay
Cell migration was measured using Transwells (pore size 8 mM; Becton Dickenson) placed in 24-well plates. 3 Â 10 5 HUVECs, which had previously been transfected with siRNA, were trypisinized and neutralized with TNS and were suspended on top of the transwell membrane in 500 ml of basal EBM supplemented with 0.1% BSA and with 750 ml basal EBM containing chemoattractants as indicated in the lower wells below the transwell membrane. Cells were allowed to migrate at 37 1C for 4 h. Nonmigrated cells on the top surface of the transwell membrane were removed by swiping with a cotton swab. Cells that had migrated through pores and attached to the bottom side of the membranes were stained with Reastain Quick-Diff Kit (Reagena Ltd, Toivala, Finland) according to the manufacturer's instructions. Cells from four fields of equal size in the centre of the PET membrane were counted at Â 100 magnification using an eyepiece-indexed graticule. Each treatment was performed in duplicate.
Reverse transcription and real-time PCR Total RNA was extracted by using the RNeasy Kit (Qiagen, Crawley, West Sussex, UK) and treated with DNase I (Qiagen) for 15 min at room temperature to remove DNA. Singlestranded cDNA was synthesized from 2 mg of total RNA with oligo (dT) 12-18 primer in a 20 ml reaction volume using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). Primer pairs were designed using Prime3 software (frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and synthesised by Sigma (St Louis, MO, USA) Genosys. The primer sequences were as follows: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) sense: 5 0 -GGAGGTGAAGGTCG GAGTC-3 0 ; GAPDH antisense 5 0 -GAAGATGGTGATGG GATTTC-3 0 ; Nur77 sense 5 0 -GCTGCAGAATGACTC CACC-3 0 ; Nur77 antisense 5 0 -ACAGCAGCACTGGGCT TA-3 0 ; Egr1 sense 5 0 -TGACCGCAGAGTCTTTTCCT-3 0 ; Egr1 antisense 5 0 -TGGGTTGGTCATGCTCACTA-3 0 ; Egr2 sense 5 0 -CCTTTCCTGTCCCTCTCTCC-3 0 ; Egr2 antisense 5 0 -GTCAGACCTCAGCCCTCTTG-3 0 ; Egr3 sense 5 0 -AG GAAAACCTATGGGGAATG-3 0 ; Egr3 antisense 5 0 -GGAG CAAATGAAATGTGGGTG-3 0 . Conventional PCR was performed using the Taq PCR Master Mix Kit (Qiagen) according to the manufacturer's instructions. Real-time PCR was performed using the LightCycler-FastStart DNA Master SYBR Green I Kit and Lightcycler System (Roche Diagnostics) according to the manufacturer's protocol. PCR was conducted in duplicate for each sample and RNA preparations from at least three independent experiments were used for realtime RT-PCR. Data were normalized to the reference gene GAPDH, and are presented as the mean fold increase compared with negative control ( ± s.e.m.).
Immunoblotting
Cells were lysed with SDS-polyacrylamide gel electrophoresis sample buffer (2% SDS, 10% glycerol, 80 mM Tris-HCl and 1% b-mercaptoethanol). Equal quantities of protein were separated by 10% SDS-PAGE and electrotransferred to polyvinylidene difluoride membranes (Millipore, Watford, Herts, UK). The membranes were blocked with PBS/3% BSA for 1 h with agitation at room temperature and then Preparation of nuclear extracts and Egr activation assay Nuclear extracts were prepared using a Nuclear Extraction Kit (Active Motif, Rixensart, Belgium) according to the manufacturer's instructions. Briefly, cells treated as indicated were collected by scraping and pelleted by centrifugation at 500 r.p.m. for 5 min at 4 1C. The cell pellet was resuspended in the hypotonic buffer and incubated on ice for 15 min. Nuclei were pelleted by centrifugation at 14 000 r.p.m. for 30 s. The supernatant (cytoplasmic fraction) was removed and the nuclei were resuspended in complete lysis buffer and placed on a rocking platform at 150 r.p.m. at 4 1C for 30 min. The nuclear extract was centrifuged at 13 000 r.p.m. for 10 min at 4 1C and the supernatant fractions were frozen in aliquots at À80 1C after measuring the protein concentration using a Bio-Rad protein assay. Examination of Egr3 activation was performed by NoShift II transcription factor assay (Novagen, Nottingham, UK) according to the manufacturer's instruction. Briefly, equal amounts of nuclear extracts were incubated for 20 min at room temperature with binding solution containing biotinlabelled consensus Egr response element (EgrRE) oligonucleotides, following by further incubation for 20 min at room temperature in nuclease digestion buffer to remove the unbound oligonucleotides. The samples were then transferred into a 96-well capture plate containing oligonucleotides complementary to the tail of the Egr consensus oligonucleotides. The samples were hybridized into the capture plate at room temperature for 45 min and then were incubated with detection solution containing streptavidin-alkaline phosphatase for 30 min at room temperature. The samples were incubated with chemiluminescent substrate at 37 1C for 30 min prior to reading at a microplate luminometer. The activation of Egr was expressed as fold increase in chemiluminescence above the untreated control.
Statistical analysis
Statistical analysis was determined using two-way ANOVA or Student's t-test as indicated. A P-value of less than 0.05 was considered significant in all cases. * represents P-value less than 0.05 and ** represents P-value less than 0.01.
